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To the editor:
Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective
analysis of the EWOG-MDS study group
DNA methyltransferase-inhibiting azanucleosides have become a
mainstay of treatment of myeloid neoplasms in adult patients,1 with
5-azacytidine (azacitidine) being the agent in broadest clinical use.
Although not curative, treatment with azacitidine achieves hema-
tologic improvement and transfusion independency inmany patients
and prolongs survival.2,3 Even though most children with juvenile
myelomonocytic leukemia (JMML) qualify for allogeneic hemato-
poietic stem cell transplantation (HSCT), the acceptable toxicity of
low-dose azacitidine and its cytoreductive potentialmake it an attrac-
tive option as a bridging therapy before HSCT4 or as palliation after
1 or more transplants have failed. We previously published the ﬁrst
case report of a boy with JMML who achieved a complete clinical
and genetic remission after 8 cycles of azacitidine.5 Here, we present
a retrospective compilation of 12 children with JMMLwho received
individual off-label treatment with azacitidine before HSCT (N 5 9)
or for relapsed disease (N 5 3).
The children were treated at 11 centers November 2007-April
2012. Ten children were enrolled in the studies “98” or “2006”
of the European Working Group of Myelodysplastic Syndromes
in Childhood (EWOG-MDS; registered at www.clinicaltrials.gov
as #NCT00047268 and #NCT00662090). Approval was obtained
from the institutional review board of each institution, and par-
ental informed consent was provided according to the Declaration
of Helsinki. Two children were treated at centers not participating in
EWOG-MDS studies. One case (D644) was published previously.5 The
diagnosis of all children was centrally reviewed, and response was
evaluated according to international consensus criteria.6
The median age of the 12 patients was 4.8 years (range 0.4-9.1)
(Table 1). A total of 64 azacitidine cycles were administered (median
5.5 cycles, range 1-11). Sevenof 12 treatments consistedof100mg/m2
azacitidine per intravenous infusion on 5 consecutive days every
28 days. In the other 5 patients, the substance was administered over
5 to 7 days at a single dose of 50 to 100 mg/m2 per intravenous or
subcutaneous route every 28 to 42 days.
Severe neutropenia (#500/mL) was observed in 4 children.
Cytopenias led to dose reduction in 2 children, both treated for re-
lapse after second HSCT. Other adverse events were gastrointestinal
problems including nausea and vomiting in 2 children, skin rash in
2 children, and fatigue or slight creatinine elevation in 1 patient each.
Seven episodes of infectionwere reported for a total of 64 azacitidine
cycles (10.9%).
Of 9 children treated prior to HSCT, 3 normalized blood counts
and spleen size (scored as clinical CR) (Table 1). In 2 of these pa-
tients, monosomy 7 was present in leukemic cells but disappeared
after cycles 5 and 6, respectively. The leukemic karyotype was nor-
mal in the other child with clinical CR, precluding the assessment of
cytogenetic response. Two of the 3 CR patients featured a somatic
PTPN11 gene mutation. The mutation became undetectable after
cycle 6 in 1 child (NS002); material for mutational analysis under
azacitidine was unavailable from the other child (D827). The third
leukemia carried a somatic KRAS mutation, which was no longer
detectable after 7 cycles of azacitidine (D644).5 One child (CH058)
experienced considerable regression of spleen size and became
transfusion independent (scored as clinical PR). All 4 children
underwent HSCTafter 7 to 11 cycles.A ﬁfth child (NS001) responded
unusually early, as indicated by reduction of splenomegaly after the
ﬁrst cycle and hematologic improvement after cycle 3 (scored as
clinical PR). Azacitidine was then discontinued because of parental
choice. Three children progressed rapidly under azacitidine and
underwent expedited HSCT. One child (I255) was not evaluable
for response because of concomitant treatment. Three children with
JMML received azacitidine for leukemia recurrence after the second
HSCT. They achieved clinical PR or could be maintained in stable
disease for 4 cycles before progressing.
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In summary, this retrospective series indicates that low-dose
azacitidine is effective and tolerable in JMMLand documents 3 cases
of JMML where azacitidine induced complete clinical, cytogenetic,
and/or molecular genetic remissions before allogeneic HSCT. Im-
portantly, complete remissions without HSCT have not been doc-
umented for JMML thus far, regardless of whether conventional
cytostatic chemotherapy or newer experimental agentswere applied.7-10
Prospective clinical investigation of azacitidine, such as the ongoing
collaborative Innovative Therapies in Childhood Cancer/EWOG-
MDS phase 1/2 trial (Eudra-CT 2010-022235-10), is needed to clarify
these questions.
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Table 1. Response to azacitidine in children with JMML
Disease
status
Patient
identifier
Age (y) and
gender Cytogenetics
Mutational
group*
Azacitidine
cycles
Concomitant
treatment
Response to
azacitidine†
HSCT (total
number) Status
Follow-up
(mo)‡
Prior to first
HSCT
A062 1.1, male Del(5)(q13q33) NRAS 1 None PR Yes (2) Alive with
leukemia
38
2-3 None PD
Prior to first
HSCT
CH058 2.8, male Normal PTPN11 1-3 None SD Yes (2) Alive with
leukemia
16
4-7 None PR
Prior to first
HSCT
D644§ 1.4, male 27 KRAS 1 None PD Yes (1) Alive in
remission
62
2-4 None SD
5-8 None CR||
Prior to first
HSCT
D706 5.9, male 27 PTPN11 1 None PD Yes (3) Alive in
remission
66
Prior to first
HSCT
D712 6.3, female Normal NRAS 1 None PD Yes (1) Dead, TRM 1
Prior to first
HSCT
D827 0.4, male Normal PTPN11 1-2 6MP Not evaluable Yes (1) Alive in
remission
38
3-7 None CR{
Prior to first
HSCT
I255 9.1, male Inv(2)(p23q13), 27 No mutation 1-4 AraC, 6MP Not evaluable Yes (1) Alive in
remission
49
Prior to first
HSCT
NS001 5.4, male 27 NRAS 1-3 None PR No Dead,
progressive
disease
No data
Prior to first
HSCT
NS002 0.8, male 27 PTPN11 1 None SD Yes (1) Dead, TRM 13
2-3 None PR
4-11 None CR#
Relapse after
HSCT**
NL121 4.6, male Not done PTPN11 2-4 None SD Yes (3) Dead, third
relapse
6
1, 5-8 None PD
Relapse after
HSCT**
SC108 5.0, male Normal†† NF1 1-2 None SD Yes (2) Dead,
progressive
disease
1
3-4 None PR
5 None PD
Relapse after
HSCT**
SC156 5.3, male Normal†† PTPN11 2-4 None PR Yes (3) Dead, third
relapse
5
1, 5-6 None PD
AraC, cytarabine; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; 6MP, 6-mercaptopurine; TRM, transplantation-related mortality.
*All mutations were confirmed to be somatic. Neurofibromatosis type 1 was diagnosed clinically.
†Cycles of azacitidine with concomitant antineoplastic medication were considered not evaluable.
‡From the end of azacitidine treatment to death or last follow-up.
§This case was published previously by Furlan et al.5
||The patient reached genetic CR with disappearance of monosomy 7 and KRAS mutation after 5 and 7 cycles, respectively. Monosomy 7 was tested by fluorescence in
situ hybridization, and KRAS mutation was assessed by Sanger sequencing.
{Material for mutational studies was not available at the time of clinical CR.
#The patient reached genetic CR with disappearance of monosomy 7 and PTPN11 mutation after 6 cycles. Monosomy 7 was tested by fluorescence in situ hybridization,
and PTPN11 mutation was assessed by Sanger sequencing.
**Relapse after second HSCT.
††Last cytogenetic analysis: SC108, at start of azacitidine treatment; SC156, prior to second HSCT.
2312 CORRESPONDENCE BLOOD, 2 APRIL 2015 x VOLUME 125, NUMBER 14
For personal use only.on January 13, 2016. by guest  www.bloodjournal.orgFrom 
Markus Schmugge
Department of Hematology and Oncology, University Children’s Hospital,
Zurich, Switzerland
Ute Groß-Wieltsch
Olgahospital, Pediatrics 5 (Oncology, Hematology, Immunology,
Rheumatology, Gastroenterology, and General Pediatrics),
Klinikum Stuttgart,
Stuttgart, Germany
Andrea Canda´s
Department of Hematology and Oncology,
Pediatric Hospital Prof Dr Juan P. Garrahan,
Buenos Aires, Argentina
Andreas E. Kulozik
Department of Pediatric Oncology, Hematology and Immunology,
University of Heidelberg,
Heidelberg, Germany
Lale Olcay
Department of Pediatric Hematology,
Dr Abdurrahman Yurtaslan Ankara Oncology Training and
Research Hospital of the Ministry of Health,
Ankara, Turkey
Meinolf Suttorp
Division of Pediatric Hematology and Oncology, University Children’s Hospital,
Dresden, Germany
Ingrid Furlan
University Children’s Hospital,
Ulm, Germany
Brigitte Strahm
Division of Pediatric Hematology-Oncology,
Department of Pediatrics and Adolescent Medicine,
University Medical Center,
Freiburg, Germany
Christian Flotho
Division of Pediatric Hematology-Oncology,
Department of Pediatrics and Adolescent Medicine,
University Medical Center,
Freiburg, Germany
German Cancer Consortium (DKTK),
Heidelberg, Germany
Acknowledgments: This work was supported by Deutsche
ForschungsgemeinschaftgrantsFL345/4-1 (C.M.N.,C.F.)andCRC992-C05(C.F.).
Contribution: Annamaria C., C.M.N., and C.F. designed research, analyzed
data, and wrote themanuscript; and A.Y., M.D., H.H., M.M.v.d.H.-E., F.L., R.M.,
M.S., U.G.-W., Andrea C., A.E.K., L.O., M.S., I.F., and B.S. performed research.
Conflict-of-interest disclosure: The authors declare no competing financial
interests.
Correspondence: C. Flotho, Division of Pediatric Hematology-Oncology,
Department of Pediatrics and Adolescent Medicine, University Medical Center,
Mathildenstrasse 1, 79106 Freiburg, Germany; e-mail: christian.flotho@
uniklinik-freiburg.de.
References
1. Santini V. Novel therapeutic strategies: hypomethylating agents and beyond.
Hematology Am Soc Hematol Educ Program. 2012;2012:65-73.
2. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of
azacitidine in patients with the myelodysplastic syndrome: a study of the cancer
and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS
Survival Study Group. Efficacy of azacitidine compared with that of conventional
care regimens in the treatment of higher-risk myelodysplastic syndromes:
a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
4. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL.
Pretransplantation therapy with azacitidine vs induction chemotherapy and
posttransplantation outcome in patients with MDS. Biol Blood Marrow
Transplant. 2012;18(8):1211-1218.
5. Furlan I, Batz C, Flotho C, et al. Intriguing response to azacitidine in a patient with
juvenile myelomonocytic leukemia andmonosomy 7. Blood. 2009;113(12):2867-2868.
6. Niemeyer CM, Loh ML, Cseh A, et al. Criteria for evaluating response and
outcome in clinical trials for children with juvenile myelomonocytic leukemia.
Haematologica. 2015;100(1):17-22.
7. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin
in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;
331(25):1680-1684.
8. Niemeyer CM, Arico M, Basso G, et al; European Working Group on
Myelodysplastic Syndromes in Childhood (EWOG-MDS). Chronic
myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases.
Blood. 1997;89(10):3534-3543.
9. Castleberry RP, Loh ML, Jayaprakash N, et al. Phase II window study of the
farnesyltransferase inhibitor R115777 (Zarnestra ) in untreated juvenile
myelomonocytic leukemia (JMML): a children’s oncology group study [abstract].
Blood. 2005;106(11). Abstract 2587.
10. Bergstraesser E,HasleH,RoggeT, et al. Non-hematopoietic stemcell transplantation
treatment of juvenilemyelomonocytic leukemia: a retrospective analysis and definition
of response criteria. Pediatr Blood Cancer. 2007;49(5):629-633.
© 2015 by The American Society of Hematology
BLOOD, 2 APRIL 2015 x VOLUME 125, NUMBER 14 CORRESPONDENCE 2313
For personal use only.on January 13, 2016. by guest  www.bloodjournal.orgFrom 
doi:10.1182/blood-2015-01-619734
2015 125: 2311-2313
 
 
Christian Flotho
Andrea Candás, Andreas E. Kulozik, Lale Olcay, Meinolf Suttorp, Ingrid Furlan, Brigitte Strahm and
van den Heuvel-Eibrink, Franco Locatelli, Riccardo Masetti, Markus Schmugge, Ute Groß-Wieltsch, 
Annamaria Cseh, Charlotte M. Niemeyer, Ayami Yoshimi, Michael Dworzak, Henrik Hasle, Marry M.
 
leukemia: a retrospective analysis of the EWOG-MDS study group
Bridging to transplant with azacitidine in juvenile myelomonocytic
 
http://www.bloodjournal.org/content/125/14/2311.full.html
Updated information and services can be found at:
 (2116 articles)Transplantation    
 (1440 articles)Myeloid Neoplasia    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on January 13, 2016. by guest  www.bloodjournal.orgFrom 
